Basit öğe kaydını göster

dc.contributor.authorÖzkasap, Serdar
dc.contributor.authorYaralı, Neşe
dc.contributor.authorIşık, Pamir
dc.contributor.authorBay, Ali
dc.contributor.authorKara, Abdurrahman
dc.contributor.authorTunç, Bahattin
dc.date.accessioned2020-12-19T20:15:58Z
dc.date.available2020-12-19T20:15:58Z
dc.date.issued2013
dc.identifier.citationOzkasap, S., Yarali, N., Isik, P., Bay, A., Kara, A., & Tunc, B. (2013). The role of prohepcidin in anemia due to Helicobacter pylori infection. Pediatric hematology and oncology, 30(5), 425–431. https://doi.org/10.3109/08880018.2013.783144en_US
dc.identifier.issn0888-0018
dc.identifier.urihttps://doi.org/10.3109/08880018.2013.783144
dc.identifier.urihttps://hdl.handle.net/11436/4097
dc.descriptionPubMed: 23560993en_US
dc.description.abstractBackground: Hepcidin, a key regulator of iron homeostasis, increases when inflammation and some infections occur. It plays a critical role in macrophage iron retention, which underlies inflammation/infection caused anemia. It is known that Helicobacter pylori (HP) may lead to iron deficiency (ID) due to occult blood loss or reduced iron absorption. This study investigates the role of prohepcidin, hepcidin's precursor, in ID and ID anemia (IDA) with a concurrent HP infection. Methods: In this prospectively designed study, 15 patients with IDA and a concurrent HP infection (group 1), 11 patients with an ID and a concurrent HP infection (group 2), and 18 patients with HP infection (group 3) were observed. All groups received only HP eradication therapy. Twenty-five age- and sex-matched children without ID/IDA and HP infection were included in the study as the control group. In all groups and control group, measurements were taken for pre- and posttreatment hemoglobin, serum prohepcidin, serum ferritin, serum iron (SI), transferrin saturation, erythrocyte sedimentation rate, fibrinogen, and C-reactive protein levels. Results: The pretreatment prohepcidin levels were significantly higher only in group 1 compared to the control group (P < .05). In group 1, a significant increase in hemoglobin and SI levels and a significant reduction in prohepcidin levels were additionally observed following HP eradication treatment (P < .05). However, in groups 2 and 3, significant differences in hemoglobin, iron, and prohepcidin levels between pre- and posttreatment were not observed. Conclusion: Elevated serum prohepcidin might indicate the role of inflammation in the etiology of anemia concurrent with HP. Copyright © Informa Healthcare USA, Inc.en_US
dc.language.isoengen_US
dc.publisherTaylor & Francis Onlineen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnemiaen_US
dc.subjectHelicobacter pylorien_US
dc.subjectIron deficiencyen_US
dc.subjectProhepcidinen_US
dc.titleThe role of prohepcidin in anemia due to helicobacter pylori infectionen_US
dc.typearticleen_US
dc.contributor.departmentRTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.contributor.institutionauthorÖzkasap, Serdar
dc.identifier.doi10.3109/08880018.2013.783144
dc.identifier.volume30en_US
dc.identifier.issue5en_US
dc.identifier.startpage425en_US
dc.identifier.endpage431en_US
dc.relation.journalPediatric Hematology and Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster